ProCE Banner Activity


Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies


On-demand webcast of expert faculty presentation and case discussion on disease-modifying therapies to optimize the treatment and management of adults with spinal muscular atrophy.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 13, 2024

Expiration: March 12, 2025



Perry Shieh

Perry Shieh, MD, PhD

Professor (Health Sciences)
Departments of Neurology and Pediatrics
David Geffen School of Medicine at UCLA
University of California, Los Angeles
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC, in partnership with Cure SMA.

ProCE Banner


Supported by educational grants from Biogen and Genentech, a member of the Roche Group.


Genentech, a member of the Roche Group


Cure SMA

ProCE Banner

Target Audience

The intended audience for this educational initiative is neurologists who manage patients with spinal muscular atrophy.

Program Learning Goal

Neurologists need to modify their clinical approach to provide individualized care within the context of new treatments. The number of adults with SMA is expected to continue to grow, and thus, a greater need exists for clinicians to improve their provision of age-appropriate care and ensure adults benefit from therapeutic advances. This educational initiative will provide targeted, clear, and concise information that would help neurologists provide optimal, individualized care to their adult patients with SMA.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the unique clinical issues and psychosocial needs faced by adults with SMA

  • Assess the latest safety and efficacy data of available and emerging disease-modifying therapies for SMA in adults

  • Integrate available disease-modifying therapies for SMA into individualized, evidence-based treatment plans

  • Apply effective communication strategies to engage patients in shared decision making and reach management decisions that meet their individual needs


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Perry Shieh, MD, PhD

Professor (Health Sciences)
Departments of Neurology and Pediatrics
David Geffen School of Medicine at UCLA
University of California, Los Angeles
Los Angeles, California

Perry Shieh, MD, PhD: consultant/advisor/speaker: Alexion, Argenx, Biogen, Catalyst, CSL Behring, Genentech, Grifols, Novartis, Sarepta Therapeutics, UCB.

The planners and content peer reviewers from Clinical Care Options, LLC and CureSMA do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 13, 2024, through March 12, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and Cure SMA. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABMS Approval Statement

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) for the following ABMS Member Boards: 

ABMS Lifelong Learning CME Activity

Psychiatry and Neurology